Enteric Disease Testing and Treatment: Technologies and Global Markets
The global market for diagnostics and preventive vaccines for enteric diseases reached $6.5 billion in 2013. This market should grow to $10 billion in 2014 and about $21.9 billion in 2018, a compound annual growth rate (CAGR) of 27.3%.
- An overview of the global market for enteric disease testing and treatment.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2018.
- Information on recent developments in diagnostic technology for specific pathogens or classes of pathogens.
- A look at how poor drainage and sanitation along with overcrowding and low hygiene awareness account for the majority of enteric infection incidences globally.
- Insight into recent advances like improved stool polymerase chain reaction assays which are impacting the industry.
- Comprehensive profiles of major players in the field.
SCOPE OF THE STUDY
The scope of this study are the clinical testing and preventative vaccine markets for enteric diseases. The report also includes the clinical segment, currently approved diagnostic tests and their markets, current testing technologies, new technologies, enteric diseases, causative agents and global incidence, market projections and market share along with the latest trends and new developments in this area. This report does not include the treatment market or the research market including reagents, instruments or any accessories used for diagnostic testing sample preparation or analysis. Other enteric pathogens or intestinal cancers are outside the scope of this report.
Usha Nagavarapu, PhD, is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification including investigational new drug (IND)-enabling studies, and assisted out-licensing and portfolio development activities. Her focus areas include oncology, dermatology and cardiovascular diseases. Usha has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational costs and burdens.